期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

赫赛汀联合紫杉醇治疗HER-2过表达转移性乳腺癌 被引量：3

下载PDF
导出
摘要 目的观察赫赛汀联合紫杉醇对人类表皮生长因子受体-2(HER-2)过表达的转移性乳腺癌的治疗效果。方法将86例HER-2过度表达的转移性乳腺癌患者随机分为赫赛汀联合紫杉醇治疗组(联合组,32例)、赫赛汀治疗组(单药组,25例)和紫杉醇联合表阿霉素治疗组(常规组,29例),分别用相应药物治疗,8周为1疗程,观察各组疗效及不良反应。结果三组总有效率(RR)比较,联合组>单药组>对照组(P均<0.05);各组药物不良反应发生率比较,P>0.05。结论与赫赛汀单独应用和常规化疗相比,赫赛汀联合紫杉醇能显著提高HER-2过表达的转移性乳腺癌的疗效,且不增加不良反应。
作者 王永凤 韩建军 刘月梅
机构地区 河北工程大学附属医院
出处 《山东医药》 CAS 北大核心 2009年第46期74-75,共2页 Shandong Medical Journal
基金 邯郸市科技攻关项目(0923108058-7)
关键词 乳腺肿瘤 转移性乳腺癌 人类表皮生长因子受体-2 紫杉醇
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献6

  • 1Dent S,Verma SH,Latroille J,et al. The role of HER-2 targeted therapies in women with HER-2 overexpressing metastatic breast cancer [ J ].Curr Oncol,2009,16 ( 4 ) : 25 -35.
  • 2柳影,程颖.实体肿瘤疗效评价标准的研究[J].实用肿瘤学杂志,2004,18(2):149-152. 被引量：37
  • 3狄根红,沈镇宙,邵志敏.赫赛汀在转移性乳腺癌治疗中的应用和进展[J].实用癌症杂志,2003,18(6):664-666. 被引量：20
  • 4Rowinsky EK, Cazenave LA, Donehower RC. Taxol : a novel investi- gational antimicrotuble agent [ J ]. J Natl Cancer Inst, 1990,82 ( 15 ) : 1247 - 1259.
  • 5Argiris A, Wang X, Whalen G,et al. Synergistic interactions between tamoxifen and trastuzumab(herceptin) [ J]. Clin Cancer Res ,2004, 10(4) :1409-1420.
  • 6Baselga J, Norton L, Albanell J, et al. Recombinant humanized anti- HER-2 antibody (herceptin) enhances the antitumor activity of paclitaxel and doxombicin against HER-2/neu overexpressing human breast cancer xenografts[ J]. Cancer Res, 1998,58 ( 13 ) :2825-2831.

二级参考文献26

  • 1[1]Stern DF, Hefferman PA, Weinberg RA. p185, a product of the neu proto-oncogene,is a receptorlike protein associated with tyrosine kinase activity[J]. Mol Bell Biol, 1986,6(5): 1729.
  • 2[2]Chong D, Cooke TG, Reeve JR, et al. Quantification of EGFR and c-erbB-2 expression in preinvasive compared to invasive breast cancer[J]. Eur J Cancer, 1999,35(Suppl 4) :203.
  • 3[3]Allred DC, Clark GM, Molina R, et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer[J]. Hum Pathol, 1992,23(9) :974.
  • 4[4]Thomas E,Buzdar A,Theriault R,et al. Role of paclitaxel in adjuvant therapy of operable breast cancer: preliminary results of prospective randomised clinical trial[J]. Proc Am Soc Clin Oncol,2000,19:74.
  • 5[5]Strickland LB, Dawson PJ. The hyperplasia-to-carcinoma sequence in the breast: immunohistochemical-histologic correlations [J]. Appl Immunohistochem Mol Morphol, 2000,8 (2): 9.
  • 6[6]Cobleigh MA,Vogel CL,Tripathy D,et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metasta-tic disease [J]. J Clin Oncol, 1999,17 (9): 2639.
  • 7[7]Slamon DJ,Leyland-Jones B,Shak S,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 [J]. N Engl J Med, 2001, 344(11):783.
  • 8[8]Pegram M,Hsu S,Lewis G,et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for the treatment of human breast cancers[J]. Oncogene, 1999,18(13):2241.
  • 9[9]Leyland-Jones B. Integration of Herceptininto breast cancer treatment algorithms[J]. Anti-Cancer Drugs,2002,13(suppl): 100.
  • 10[10]Slamon D, Leyland-Jones B, Shak S, et al. Addition of Herceptin(humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer(HER2 +/MBC) markedly increases anticancer activity: a ran-domized,multinational, controlled phase Ⅲ trial [J]. Proc Am Soc Clin Oncol, 1998,17: 98a.

共引文献55

同被引文献29

引证文献3

二级引证文献19

山东医药
2009年 第46期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部